Post by icemandios on Oct 25, 2023 13:18:03 GMT
Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests
AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA. The test is expected to be launched as a part of the Company’s OvaSuite portfolio in collaboration with a consortium of world-renowned academic researchers under a previously announced licensing agreement.
The study showed the addition of miRNA improved the detection of early-stage ovarian cancers, and that diagnostic performance improved even further when using a combination of approaches, including miRNA, proteins and metadata. The data suggest that using combined approaches could improve the triaging of patients with suspected ovarian cancers.
“These data are very exciting and show the potential of miRNAs as a powerful tool in improving a number of diagnostic tests,” said Dr. Elias.
Nicole Sandford, President and Chief Executive Officer of Aspira Women’s Health said, “We are very pleased to see such promising initial findings from our collaboration with the Dana-Farber Cancer Institute. The analysis shows the potential for improving ovarian cancer diagnostics by combining our trusted technology with miRNA. It is exactly findings like these that give us hope that one day we will be able to detect ovarian cancer before it has progressed to its deadliest stages.”
A copy of the poster can be found on the Research and Professional Guidelines section under Providers of the Aspira Women’s Health corporate website.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite SM , which includes OvaWatch SM , a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus ® combines our FDA-cleared products, Ova1 ® and Overa ® , to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck SM , Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com .